Piper Sandler Lowers Biohaven Pharmaceutical (NYSE:BHVN) Price Target to $149.00

Biohaven Pharmaceutical (NYSE:BHVNGet Rating) had its target price reduced by equities researchers at Piper Sandler to $149.00 in a report released on Tuesday, Stock Target Advisor reports. The firm currently has a “na” rating on the stock. Piper Sandler’s price objective would suggest a potential upside of 4.31% from the stock’s previous close.

Other equities research analysts have also issued research reports about the company. SVB Leerink lowered Biohaven Pharmaceutical from an “outperform” rating to a “market perform” rating and set a $150.00 price target on the stock. in a research note on Wednesday, May 11th. Cantor Fitzgerald downgraded Biohaven Pharmaceutical from an “overweight” rating to a “neutral” rating in a report on Wednesday, May 11th. Mizuho boosted their price target on Biohaven Pharmaceutical from $144.00 to $154.00 and gave the company a “buy” rating in a report on Thursday, March 3rd. HC Wainwright downgraded Biohaven Pharmaceutical from a “buy” rating to a “neutral” rating in a report on Wednesday, May 11th. Finally, Morgan Stanley decreased their price objective on shares of Biohaven Pharmaceutical from $148.00 to $146.00 and set an “equal weight” rating for the company in a research report on Wednesday, April 6th. Six equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Biohaven Pharmaceutical has a consensus rating of “Hold” and a consensus target price of $151.73.

BHVN traded down $0.16 during trading on Tuesday, reaching $142.84. The company’s stock had a trading volume of 28,362 shares, compared to its average volume of 1,233,233. Biohaven Pharmaceutical has a 52-week low of $76.83 and a 52-week high of $151.51. The company’s fifty day moving average price is $116.43 and its 200-day moving average price is $120.76. The company has a market capitalization of $10.07 billion, a price-to-earnings ratio of -12.06 and a beta of 1.20.

Biohaven Pharmaceutical (NYSE:BHVNGet Rating) last announced its quarterly earnings data on Tuesday, May 10th. The company reported ($2.97) earnings per share for the quarter, missing analysts’ consensus estimates of ($2.52) by ($0.45). During the same quarter in the prior year, the firm earned ($4.21) earnings per share. As a group, research analysts anticipate that Biohaven Pharmaceutical will post -9.85 EPS for the current year.

In other Biohaven Pharmaceutical news, CAO George C. Clark sold 4,200 shares of the firm’s stock in a transaction that occurred on Tuesday, May 10th. The shares were sold at an average price of $141.50, for a total value of $594,300.00. Following the sale, the chief accounting officer now owns 4,065 shares in the company, valued at $575,197.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 12.40% of the stock is currently owned by company insiders.

Institutional investors have recently bought and sold shares of the stock. Two Sigma Advisers LP purchased a new position in Biohaven Pharmaceutical in the third quarter valued at about $5,404,000. Myriad Asset Management Ltd. acquired a new position in shares of Biohaven Pharmaceutical in the 4th quarter worth approximately $1,984,000. Ensign Peak Advisors Inc grew its position in Biohaven Pharmaceutical by 30.9% during the 4th quarter. Ensign Peak Advisors Inc now owns 122,413 shares of the company’s stock worth $16,870,000 after acquiring an additional 28,921 shares during the last quarter. Balyasny Asset Management LLC bought a new stake in Biohaven Pharmaceutical during the 3rd quarter worth approximately $4,785,000. Finally, Profund Advisors LLC bought a new stake in Biohaven Pharmaceutical during the 3rd quarter worth approximately $1,531,000. 88.03% of the stock is owned by hedge funds and other institutional investors.

About Biohaven Pharmaceutical (Get Rating)

Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological and neuropsychiatric diseases, and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as developing Rimegepant for preventive treatment of migraine; Zavegepant that is in phase III clinical trials for acute and preventive treatment of migraine, as well as respiratory complications and non-migraine studies; and BHV-3100 for non-migraine indications.

Featured Articles

Stock Target Advisor logo

Analyst Recommendations for Biohaven Pharmaceutical (NYSE:BHVN)

Receive News & Ratings for Biohaven Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.